Pharmalot - STAT

Pharmalot

Phlow CEO speaks out on criticism of his record, plans for a drug ingredient stockpile, and a huge government contract

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: Coronavirus vaccine may not be a cure-all; hydroxychloroquine fails in a Covid-19 study

By Ed Silverman

Pharmalot

In a tale of two Mercks, the German company wins a court battle over its U.S. rival

By Ed Silverman

Pharmalot

After years of manufacturing problems, Akorn files for bankruptcy protection

By Ed Silverman

Pharmalot

U.S. gives up to $1.2 billion to AstraZeneca for Covid-19 vaccine

By Ed Silverman

Pharmalot

Pharmalittle: Trump’s Covid-19 vaccine chief has worrisome conflicts; U.S. provides $1.2 billion for AstraZeneca vaccine

By Ed Silverman

Pharmalot

Biosimilars got the cold shoulder from health plans when it came to preferred coverage

By Ed Silverman

Pharmalot

Pharmalittle: Experts say wait-and-see about Moderna’s Covid-19 vaccine; J&J will stop selling talc products in the U.S.

By Ed Silverman

Pharmalot

CEO tapped by Trump to make generic drugs during pandemic has a dicey track record

By Ed Silverman

Pharmalot

Pharmalittle: White House signs deal for U.S.-made generics to fight Covid-19; Gilead expands remdesivir donations

By Ed Silverman

Pharmalot

Despite skepticism, Gilead’s remdesivir could become a ‘multi-year commercial opportunity’

By Ed Silverman

Pharmalot

EMA urged to release full clinical trial data upon authorizing Covid-19 treatments

By Ed Silverman

Pharmalot

Pharmalittle: U.K. will get first access to an AstraZeneca Covid-19 vaccine; VA will continue using old malaria drug

By Ed Silverman

Pharmalot

WHO embraces plan for Covid-19 intellectual property pool

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: France piles pressure on Sanofi over Covid-19 vaccine; GOP fails to land a punch on Bright

By Ed Silverman

Pharmalot

Women and Black patients are poorly represented in clinical trials, analysis finds

By Ed Silverman

Pharmalot

Pharmalittle: Sanofi walks back Covid-19 vaccine remarks; Trump to name vaccine czar with conflicts

By Ed Silverman

Pharmalot

CVS long-term care pharmacy pays $15 million penalty for failing to track opioids

By Ed Silverman

Pharmalot

World Health Assembly draft resolution boosts access to Covid-19 medicines

By Ed Silverman

Pharmalot

Pharmalittle: FDA rejects drug from Bristol and Bluebird; Gilead signs deals to widen access to remdesivir

By Ed Silverman

Pharmalot

Gilead signs licenses for generic companies to make and sell remdesivir in 127 countries

By Ed Silverman

Pharmalot

Pharmalittle: Birx acknowledges remdesivir distribution was flawed; Moderna gets FDA fast track for Covid-19 vaccine

By Ed Silverman

Pharma

Pharmalittle: Hackers linked to Iran sought Gilead Covid-19 data; NIH to test remdesivir with a Lilly drug

By Ed Silverman

Experts push for a ‘seal of approval’ to improve the quality of medicines

A pharma effort to work with European officials to develop needed drugs is a ‘failure’

Pharmalittle: Merck enters Covid-19 vaccine race; pharma alarmed by push for U.S.-only supply chain

First generic version of Gilead’s remdesivir will be sold by a Bangladesh drug maker

Phlow CEO speaks out on criticism of his record, plans for a drug ingredient stockpile, and a huge government contract

Up and down the ladder: The latest comings and goings

Pharmalittle: Coronavirus vaccine may not be a cure-all; hydroxychloroquine fails in a Covid-19 study

In a tale of two Mercks, the German company wins a court battle over its U.S. rival

After years of manufacturing problems, Akorn files for bankruptcy protection

U.S. gives up to $1.2 billion to AstraZeneca for Covid-19 vaccine

Pharmalittle: Trump’s Covid-19 vaccine chief has worrisome conflicts; U.S. provides $1.2 billion for AstraZeneca vaccine

Biosimilars got the cold shoulder from health plans when it came to preferred coverage

Pharmalittle: Experts say wait-and-see about Moderna’s Covid-19 vaccine; J&J will stop selling talc products in the U.S.

CEO tapped by Trump to make generic drugs during pandemic has a dicey track record

Pharmalittle: White House signs deal for U.S.-made generics to fight Covid-19; Gilead expands remdesivir donations

Despite skepticism, Gilead’s remdesivir could become a ‘multi-year commercial opportunity’

EMA urged to release full clinical trial data upon authorizing Covid-19 treatments

Pharmalittle: U.K. will get first access to an AstraZeneca Covid-19 vaccine; VA will continue using old malaria drug

WHO embraces plan for Covid-19 intellectual property pool

Up and down the ladder: The latest comings and goings

Pharmalittle: France piles pressure on Sanofi over Covid-19 vaccine; GOP fails to land a punch on Bright

Women and Black patients are poorly represented in clinical trials, analysis finds

Pharmalittle: Sanofi walks back Covid-19 vaccine remarks; Trump to name vaccine czar with conflicts

CVS long-term care pharmacy pays $15 million penalty for failing to track opioids

World Health Assembly draft resolution boosts access to Covid-19 medicines

Pharmalittle: FDA rejects drug from Bristol and Bluebird; Gilead signs deals to widen access to remdesivir

Gilead signs licenses for generic companies to make and sell remdesivir in 127 countries

Pharmalittle: Birx acknowledges remdesivir distribution was flawed; Moderna gets FDA fast track for Covid-19 vaccine

Pharmalittle: Hackers linked to Iran sought Gilead Covid-19 data; NIH to test remdesivir with a Lilly drug